Your browser is no longer supported. Please, upgrade your browser.
Settings
KMPH KemPharm, Inc. daily Stock Chart
KMPH [NASD]
KemPharm, Inc.
Index- P/E- EPS (ttm)-2.26 Insider Own0.30% Shs Outstand25.66M Perf Week19.29%
Market Cap42.85M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float23.82M Perf Month25.56%
Income-42.50M PEG- EPS next Q-0.46 Inst Own33.30% Short Float3.40% Perf Quarter-16.08%
Sales- P/S- EPS this Y-6.40% Inst Trans-4.64% Short Ratio4.23 Perf Half Y-33.47%
Book/sh-2.80 P/B- EPS next Y53.70% ROA-171.30% Target Price9.25 Perf Year-73.28%
Cash/sh0.52 P/C3.20 EPS next 5Y- ROE53.10% 52W Range1.15 - 6.85 Perf YTD-6.18%
Dividend- P/FCF- EPS past 5Y-7.50% ROI- 52W High-75.62% Beta1.28
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low45.22% ATR0.12
Employees33 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)60.00 Volatility7.29% 8.19%
OptionableYes Debt/Eq- EPS Q/Q74.00% Profit Margin- Rel Volume0.49 Prev Close1.59
ShortableYes LT Debt/Eq- EarningsMay 30 AMC Payout- Avg Volume191.27K Price1.67
Recom1.50 SMA208.25% SMA509.39% SMA200-32.45% Volume93,250 Change5.03%
Sep-21-18Resumed Oppenheimer Outperform
Feb-26-18Reiterated Canaccord Genuity Buy $7 → $11
Jun-28-17Initiated ROTH Capital Buy $8
May-06-16Reiterated RBC Capital Mkts Outperform $22 → $14
Sep-18-15Reiterated Oppenheimer Outperform $20 → $28
Aug-14-15Reiterated RBC Capital Mkts Outperform $18 → $22
Jun-15-15Reiterated Canaccord Genuity Buy $18 → $22
May-11-15Initiated RBC Capital Mkts Outperform $18
May-11-15Initiated Canaccord Genuity Buy $18
May-14-19 04:05PM  KemPharm Reports First Quarter 2019 Results GlobeNewswire
Apr-20-19 09:06AM  Penny Stocks to Buy Using Technical Analysis for April 2019 Investopedia
Apr-11-19 04:17PM  KemPharm Completes KP415 Pre-NDA Meeting with FDA GlobeNewswire
Mar-15-19 05:41PM  Edited Transcript of KMPH earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 07:30AM  KemPharm Provides Update on APADAZ® Formulary Adoption GlobeNewswire
Mar-07-19 10:58AM  Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To Breakeven Simply Wall St.
Mar-05-19 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire -5.48%
Feb-28-19 04:05PM  KemPharm Reports Q4 and FY 2018 Results GlobeNewswire -8.91%
02:30PM  KemPharm, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-19 04:15PM  KemPharm to Report Fourth Quarter and Year End 2018 Results GlobeNewswire
Jan-29-19 07:30AM  KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate GlobeNewswire
Jan-21-19 10:44AM  What You Must Know About KemPharm, Inc.s (NASDAQ:KMPH) Beta Value Simply Wall St.
Jan-18-19 07:30AM  KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting GlobeNewswire
Jan-07-19 07:30AM  KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP) GlobeNewswire
Jan-02-19 07:30AM  New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire +11.24%
Dec-19-18 07:30AM  KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio GlobeNewswire -5.53%
Dec-12-18 07:30AM  KemPharm Presents Poster at ACNPs 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX) GlobeNewswire
Dec-11-18 08:08AM  KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing PR Newswire
Dec-04-18 08:35AM  Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th PR Newswire
Dec-03-18 07:30AM  KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th PR Newswire
Nov-26-18 02:44PM  What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)? Simply Wall St. -7.22%
Nov-21-18 08:55AM  Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-18 09:31PM  Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -6.25%
Nov-13-18 07:30AM  KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder GlobeNewswire
Nov-08-18 04:05PM  KemPharm, Inc. Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 07:30AM  KemPharm to Report Third Quarter 2018 Results GlobeNewswire +10.19%
Oct-30-18 04:05PM  KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ® GlobeNewswire
Oct-24-18 07:30AM  KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting GlobeNewswire -18.07%
Oct-23-18 07:30AM  KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications GlobeNewswire
Oct-11-18 04:05PM  KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Oct-05-18 10:01AM  Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings MarketWatch -36.36%
09:24AM  KemPharm Announces Pricing of Public Offering of Common Stock GlobeNewswire
Oct-04-18 04:07PM  KemPharm Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-03-18 04:41PM  KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Sep-17-18 07:30AM  KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -5.83%
Sep-12-18 10:12AM  KemPharm Posts Positive Top-Line Results on KP415 Prodrug Zacks +6.19%
Sep-11-18 07:30AM  KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -7.18%
Sep-05-18 07:30AM  KemPharm to Present at Two Healthcare Investor Conferences During September 2018 GlobeNewswire
Aug-09-18 04:05PM  KemPharm, Inc. Reports Second Quarter 2018 Results GlobeNewswire
Aug-01-18 07:30AM  KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference GlobeNewswire +7.32%
Jul-31-18 07:30AM  KemPharm, Inc. to Report Second Quarter 2018 Results GlobeNewswire +5.13%
Jul-17-18 08:41AM  Options Traders Expect Huge Moves in KemPharm (KMPH) Stock Zacks
Jul-10-18 10:37AM  KemPharm Stock Down Despite Positive Data on ADHD Candidate Zacks -11.20%
Jul-09-18 12:46PM  Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results Yahoo Finance Video -7.41%
11:42AM  KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints Benzinga
08:31AM  Trump to reshape Supreme Court for decades to come Yahoo Finance Video
07:20AM  Yahoo Finance Live: Market Movers - Jul 9th, 2018 Yahoo Finance Video
07:13AM  KemPharm's stock soars after ADHD drug trial meets primary endpoints MarketWatch
07:00AM  KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD GlobeNewswire
May-23-18 12:00PM  Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst Benzinga
May-18-18 11:07AM  Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)? Simply Wall St.
May-11-18 01:40PM  KemPharm Stock Breaks Out on Clinical Trial Results Investopedia +11.32%
May-10-18 09:07PM  Will KemPharm Incs (NASDAQ:KMPH) Earnings Grow Over The Next Few Years? Simply Wall St.
04:05PM  KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results GlobeNewswire
May-01-18 07:30AM  KemPharm, Inc. to Report First Quarter 2018 Results GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine ACCESSWIRE
Mar-29-18 08:47PM  Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH) Simply Wall St.
04:05PM  KemPharm Reports Fourth Quarter and Year End 2017 Results GlobeNewswire
12:00PM  KemPharm, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 07:30AM  KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results GlobeNewswire +14.29%
Mar-20-18 07:30AM  KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD GlobeNewswire +6.06%
Mar-06-18 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire
Mar-05-18 04:35PM  At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy? Simply Wall St.
Feb-26-18 10:06AM  Heres Whats Moving KemPharm And Puma Biotechnology Market Exclusive
Feb-23-18 03:38PM  KemPharm's opioid painkiller gets FDA approval, shares soar Reuters +14.03%
02:00PM  FDA approves KemPharm's opioid painkiller Reuters
02:00PM  KemPharm Announces FDA Approval of Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain GlobeNewswire
Feb-19-18 03:31PM  Why KemPharm Incs (NASDAQ:KMPH) CEO Salary Matters To You Simply Wall St.
Feb-13-18 07:30AM  KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Jan-31-18 07:30AM  KemPharm to Present at The MoneyShow Orlando Investor Conference GlobeNewswire +7.76%
Jan-25-18 07:50AM  Blog Exposure - KemPharm Announces Patent Grant for KP606 and KP511-Related Family ACCESSWIRE
Jan-23-18 07:30AM  KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone GlobeNewswire
Jan-08-18 07:30AM  KemPharm Initiates Pivotal Efficacy Trial of KP415 GlobeNewswire +6.18%
Dec-12-17 02:14PM  Should You Be Concerned About KemPharm Incs (undefined:KMPH) Investors? Simply Wall St.
Nov-16-17 07:30AM  KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA GlobeNewswire
Nov-09-17 04:05PM  KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update GlobeNewswire
08:15AM  How Much is KemPharm Incs (KMPH) CEO Getting Paid? Simply Wall St.
Nov-06-17 07:30AM  KemPharm Receives USAN Approval for Asalhydromorphone as Nonproprietary Name for Novel Prodrug Candidate, KP511 GlobeNewswire
Nov-02-17 07:30AM  KemPharms KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies GlobeNewswire
Nov-01-17 04:30PM  KemPharm, Inc. to Report Third Quarter 2017 Results GlobeNewswire -5.26%
Oct-06-17 07:00AM  Featured Company News - KemPharm Signs Technology Licensing Agreement with Genco to Develop Prodrug-Based Therapy for Pediatric Indications of Tourettes syndrome with ADHD ACCESSWIRE -7.93%
Oct-04-17 07:30AM  KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourettes Syndrome with ADHD GlobeNewswire
Sep-20-17 07:30AM  KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate GlobeNewswire
Sep-12-17 07:15AM  KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz NDA GlobeNewswire
Aug-31-17 07:30AM  KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire +5.17%
Aug-10-17 04:05PM  KemPharm, Inc. Reports Second Quarter 2017 Results GlobeNewswire
02:00PM  Investor Network: KemPharm, Inc. to Host Earnings Call ACCESSWIRE
07:30AM  KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial GlobeNewswire
Aug-08-17 07:30AM  KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety GlobeNewswire
Aug-03-17 07:30AM  KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Aug-01-17 07:30AM  KemPharm, Inc. to Report Second Quarter 2017 Results GlobeNewswire
Jun-29-17 10:40AM  KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline Zacks +5.63%
Jun-28-17 07:30AM  KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate GlobeNewswire
Jun-26-17 04:05PM  KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone GlobeNewswire
Jun-09-17 07:30AM  KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids GlobeNewswire
Jun-01-17 07:30AM  KemPharm Announces Addition to Leadership Team GlobeNewswire
May-10-17 04:05PM  KemPharm, Inc. Reports First Quarter 2017 Results GlobeNewswire
10:00AM  Investor Network: KemPharm, Inc. to Host Earnings Call Accesswire
May-01-17 07:30AM  KemPharm, Inc. to Report First Quarter 2017 Results GlobeNewswire
Mar-28-17 04:28PM  KEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mickle Travis CPresident & CEOOct 12Buy2.555,00012,7641,703,117Oct 12 04:35 PM
Johnson Gordon KChief Business OfficerOct 12Buy2.611,0002,61010,000Oct 12 04:12 PM
Sangiovanni Timothy J.VP, Corporate ControllerOct 12Buy2.501,5003,7503,000Oct 15 04:28 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerOct 11Buy2.546501,6522,750Oct 11 06:52 PM
Sangiovanni Timothy J.VP, Corporate ControllerOct 11Buy2.551,5003,8251,500Oct 15 04:28 PM
Johnson Gordon KChief Business OfficerOct 10Buy2.623,0007,8479,000Oct 12 04:12 PM
Delaware Street Capital Master10% OwnerOct 05Buy3.002,000,0006,000,0004,095,914Oct 09 04:01 PM
Delaware Street Capital Master10% OwnerJul 30Buy4.00304,2831,217,1322,095,914Aug 01 04:05 PM